Raloxifene Use for The Heart

Completed · Phase 3 · Has a placebo group

Conditions studied: Cardiovascular Diseases, Breast Neoplasms

In brief

The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.

Key facts

Study ID

NCT00190593

Run by

Eli Lilly and Company

People needed

10000

Starts

1998-06-01

Expected to finish

2005-11-01

Last updated by the study team

2007-01-26

Who can join

Age: 55 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal women with established coronary heart disease or at risk for a major coronary event.

You may not qualify if…

• Postmenopausal symptoms that required estrogen replacement therapy.
• Suspected or known history of breast or endometrial carcinoma.
• Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis.
• New York Heart Association classes III or IV heart failure.

Where it is running

• For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.